


To outperform the Continental European market sector of companies of large and mid-size market capitalisation, while maintaining an adequate spread of risk.
| Name | % Net Assets | 
|---|---|
| Novartis | 3.7% | 
| Royal Dutch Petroleum | 3.6% | 
| Sanofi-Aventis | 3.4% | 
| UBS | 2.5% | 
| Total | 2.3% | 
| Koninklijke KPN | 2.1% | 
| E.ON AG | 2.1% | 
| Vivendi Universal | 2.0% | 
| ING Group | 1.9% | 
| Philips Electronics | 1.7% | 
| Key | % Net Assets | 
|---|---|
| 3.7% | |
| 3.6% | |
| 3.4% | |
| 2.5% | |
| 86.8% | 
| Date | n/a | 
|---|---|
| Bid | 0.00 | 
| Offer | 0.00 | 
| Currency | n/a | 
| Change | 0.00 | 
| % | n/a | 
| YTD change | 0.00 | 
| YTD % | n/a | 
| Fund Inception | 03/07/2000 | 
|---|---|
| Fund Manager | Morgan Stanley Investment Mgt Ltd | 
| TER | - | 
| Minimum Investment | |
|---|---|
| Initial | 100000 | 
| Additional | n/a | 
| Savings | n/a | 
| Charges | |
|---|---|
| Initial | 5.00% | 
| Annual Mang't | 1.40% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| Standard deviation | 0.02 | 
| Sharpe ratio | 0.07 | 
You are here: research